CD52 Products

Description

CD52, also known as CAMPATH-1 antigen, HE5, and gp20, is a cell surface glycoprotein that can be targeted to induce immune suppression by complement-mediated cell lysis (1, 2). Mature human CD52 is a 12 amino acid peptide that is tethered to the cell surface with a GPI linkage (3). It carries a large tissue-specific carbohydrate structure which increases the molecular weight of CD52 to 15-20 kDa (3-5). CD52 is expressed on lymphocytes, monocytes, monocycte-derived dendritic cells, eosinophils, and neutrophils (6-8), as well as on mature spermatozoa and epithelial cells lining the male genital tract (5, 9, 10). It protects sperm against anti-sperm antibodies by binding to C1q and inhibiting complement activation (11). CD52 ligation on CD4+ T cells induces a suppressive population of cells that release soluble CD52 which then binds to Siglec-10 (12-14). This interaction inhibits the proliferation of activated T cells and the cytotoxic function of autoimmune CD8+ T cells in type 1 diabetes (13). Our Avi-tag Biotinylated human CD52 Fc chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Bioinformatics

Uniprot	P31358.1
Product By Gene ID	1043
Alternate Names	Cambridge pathology 1 antigen CAMPATH-1 antigen CAMPATH-1 CD52 antigen (CAMPATH-1 antigen) CD52 antigen CD52 molecule CD52 CDW52 antigen (CAMPATH-1 antigen) CDw52 Epididymal secretory protein E5 He5 HEL-S-171mP Human epididymis-specific protein 5

Related CD52 Blog Posts

Check out the latest blog posts on CD52.

Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach...    Read more.

Read more CD52 related blogs.